Get E&O weekly. | Subscribe | Digital health research from Brian Dolan.
Welcome to E&O.
Last week's newsletter had a 71 percent open rate. Here's what's happening this week:
- A warm welcome to all of the new E&O enterprise subscribers! And a reminder: If your company has an enterprise subscription, any and all of your coworkers are entitled to an E&O membership. So feel free to have your colleagues send me an email if they'd like full access. For those of you looking to make E&O available to your entire team or company, head on over to the E&O pricing page here for more info.
- Better Therapeutics published its fifth study: This one assesses economic impact of the company's digital therapeutics for type 2 diabetes and hypertension. Read this summary or the full study here.
- Biofourmis announced a second FDA 510(k) clearance (first one was in May), this time for its Biovitals